2041-57-8

Basic information

• Product Name: (1-AMINOMETHYL-CYCLOHEXYL)-METHANOL
• Synonyms: (1-AMINOMETHYL-CYCLOHEXYL)-METHANOL;1-(aminomethyl)Cyclohexanemethanol;1-(Aminomethyl)cyclohexanemethanol HCl
• CAS NO: 2041-57-8
• Molecular Formula: C₈H₁₇NO
• Molecular Weight: 143.23
• Mol File: 2041-57-8.mol
• Article Data: 5

Chemical Properties

• Appearance: /
• Storage Temp.: 2-8°C
• CAS DataBase Reference: (1-AMINOMETHYL-CYCLOHEXYL)-METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (1-AMINOMETHYL-CYCLOHEXYL)-METHANOL(2041-57-8)
• EPA Substance Registry System: (1-AMINOMETHYL-CYCLOHEXYL)-METHANOL(2041-57-8)

Safety Data

• Hazardous Substances Data: 2041-57-8(Hazardous Substances Data)

Usage

General Description

(1-aminomethyl-cyclohexyl)-methanol is a chemical compound with the molecular formula C8H17NO. It is a colorless liquid with a faint odor and is soluble in water. It is primarily used as an intermediate in the production of pharmaceuticals and other organic compounds. The compound may have potential applications in the fields of medicine, agriculture, and material science due to its unique chemical structure and properties. However, it is important to handle this compound with care, as it may cause irritation to the skin, eyes, and respiratory system upon contact or inhalation.

Upstream product

• 1130-21-8 ethyl 1-cyanocyclohexane-1-carboxylate 
• 111-24-0 1,5-dibromo-pentane 
• 227203-35-2 trans aminomethylcyclohexanecarboxylic acid 
• 58920-80-2 methyl 1-cyanocyclohexane-1-carboxylate 

Downstream Products

• 223763-92-6 tert-butyl [(1-(hydroxymethyl)cyclohexyl)methyl]carbamate 
• 956126-30-0 N-(1-naphthyl)-N'-(1-hydroxy-2,2-pentamethylene)propylthiourea 

Relevant articles and documents

Design, Synthesis, and in vitro Evaluation of P2X7 Antagonists

The P2X7 receptor is a promising target for the treatment of various diseases due to its significant role in inflammation and immune cell signaling. This work describes the design, synthesis, and in vitro evaluation of a series of novel derivatives bearing diverse scaffolds as potent P2X7 antagonists. Our approach was based on structural modifications of reported (adamantan-1-yl)methylbenzamides able to inhibit the receptor activation. The adamantane moieties and the amide bond were replaced, and the replacements were evaluated by a ligand-based pharmacophore model. The antagonistic potency of the synthesized analogues was assessed by two-electrode voltage clamp experiments, using Xenopus laevis oocytes that express the human P2X7 receptor. SAR studies suggested that the replacement of the adamantane ring by an aryl-cyclohexyl moiety afforded the most potent antagonists against the activation of the P2X7 cation channel, with analogue 2-chloro-N-[1-(3-(nitrooxymethyl)phenyl)cyclohexyl)methyl]benzamide (56) exhibiting the best potency with an IC50 value of 0.39 μΜ.

HETEROCYCLIC COMPOUNDS AND USE THEREOF AS MODULATORS OF TYPE III RECEPTOR TYROSINE KINASES

Provided herein are heterocyclic compounds for treatment of CSF1R, FLT3, KIT, and/or PDGFRβ kinase mediated diseases. Also provided are pharmaceutical compositions comprising the compounds and methods of using the compounds and compositions.

Synthesis and biological evaluation of cryptophycin analogs with substitution at C-6 (fragment C region)

Analogs of the antitumor agents cryptophycins 1 and 8 with dialkyl substitution at C-6 (fragment C) were synthesized and evaluated for in vitro cytotoxicity against human leukemia cells (CCRF-CEM). The activity of these analogs decreased as the size of the substituents at C-6 increased. The C-6 spirocylopropyl compound (2g) was highly potent in vitro and showed excellent antitumor activity in animal models.